Relevant bibliographies by topics / Paclitaxel (Taxol)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Paclitaxel (Taxol)'

Author: Grafiati
Published: 4 June 2021
Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Paclitaxel (Taxol).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Paclitaxel (Taxol)"

1

Rowinsky, Eric K., and Ross C. Donehower. "Paclitaxel (Taxol)." New England Journal of Medicine 332, no. 15 (1995): 1004–14. http://dx.doi.org/10.1056/nejm199504133321507.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kohler, David R., and Barry R. Goldspiel. "Paclitaxel (Taxol)." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 14, no. 1 (1994): 3–34. http://dx.doi.org/10.1002/j.1875-9114.1994.tb02785.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stull, Dean P., Thomas A. Scales, Randy Daughenbaugh, Neil A. Jans, and David T. Bailey. "Taxol® (Paclitaxel)." Applied Biochemistry and Biotechnology 54, no. 1-3 (1995): 133–40. http://dx.doi.org/10.1007/bf02787915.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Faivre, Sandrine, Fran??ois Goldwasser, Patrick Souli??, and Jean-Louis Misset. "Paclitaxel (Taxol?? )-associated junctional tachycardia." Anti-Cancer Drugs 8, no. 7 (1997): 714–16. http://dx.doi.org/10.1097/00001813-199708000-00011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Martin, Virginia. "Overview of Paclitaxel (TAXOL®)." Seminars in Oncology Nursing 9, no. 4 (1993): 2–5. http://dx.doi.org/10.1016/s0749-2081(16)30035-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Arbuck, Susan G., Andrew Dorr, and Michael A. Friedman. "Paclitaxel (Taxol) in Breast Cancer." Hematology/Oncology Clinics of North America 8, no. 1 (1994): 121–40. http://dx.doi.org/10.1016/s0889-8588(18)30191-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Raymond, E., S. Cartier, C. Canuel, et al. "Extravasation de paclitaxel (Taxol®)." La Revue de Médecine Interne 16, no. 2 (1995): 141–42. http://dx.doi.org/10.1016/0248-8663(96)80679-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Weaver, Beth A. "How Taxol/paclitaxel kills cancer cells." Molecular Biology of the Cell 25, no. 18 (2014): 2677–81. http://dx.doi.org/10.1091/mbc.e14-04-0916.

Full text
Abstract:
Taxol (generic name paclitaxel) is a microtubule-stabilizing drug that is approved by the Food and Drug Administration for the treatment of ovarian, breast, and lung cancer, as well as Kaposi's sarcoma. It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma, and leukemia. Paclitaxel has long been recognized to induce mitotic arrest, which leads to cell death in a subset of the arrested population. However, recent evidence demonstrates that intratumoral concentrations of paclitaxel are too low to cause mitotic
APA, Harvard, Vancouver, ISO, and other styles
9

Perry, J. R., and E. Warner. "Transient encephalopathy after paclitaxel (Taxol) infusion." Neurology 46, no. 6 (1996): 1596–99. http://dx.doi.org/10.1212/wnl.46.6.1596.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Spiridonidis, C. H. "Paclitaxel (Taxol): A novel antineoplastic agent." Drugs of Today 29, no. 4 (1993): 295. http://dx.doi.org/10.1358/dot.1993.29.4.237522.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Paclitaxel (Taxol)"

1

Colony, James Lynn. "Studies on the biosynthesis of taxol /." Thesis, Connect to this title online; UW restricted, 2000. http://hdl.handle.net/1773/11587.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhao, Zhiyang. "Studies on water-soluble taxol derivatives." Thesis, This resource online, 1991. http://scholar.lib.vt.edu/theses/available/etd-11242009-020141/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kreilein, Matthew M. "Progress toward the total synthesis of paclitaxel (taxol)." The Ohio State University, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=osu1117063322.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Targa, Benjamin. "Dialogue entre SEPT9_i1 et polyglutamylation de la tubuline : coopération dans la chimiorésistance aux taxanes et dans la localisation microtubulaire des filaments de septines." Thesis, Université Paris-Saclay (ComUE), 2015. http://www.theses.fr/2015SACLS183.

Full text
Abstract:
L’émergence de phénomènes de résistance au paclitaxel (Taxol®), un agent stabilisateur de microtubules (MTs), est un obstacle majeur au succès de cette molécule dans les chimiothérapies anticancéreuses et limite son utilisation. Au laboratoire, un nouveau mécanisme de résistance au Taxol® a été mis en évidence dans les cellules tumorales mammaires MDA-MB 231. Il est basé sur une restauration de la dynamique microtubulaire et implique i) deux modifications post-traductionnelles de la tubuline (MPTs), la détyrosination/retyrosination et la polyglutamylation et ii) la surexpression et la relocali
APA, Harvard, Vancouver, ISO, and other styles
5

Yang, Chao. "Syntheses and Bioactivities of Targeted and Conformationally Restrained Paclitaxel and Discodermolide Analogs." Diss., Virginia Tech, 2008. http://hdl.handle.net/10919/28942.

Full text
Abstract:
Paclitaxel was isolated from the bark of <i>Taxus brevifolia</i> in the late 1960s. It exerts its biological effect by promoting tubulin polymerization and stabilizing the resulting microtubules. Paclitaxel has become one of the most important current drugs for the treatment of breast and ovarian cancers. Studies aimed at understanding the biologically active conformation of paclitaxel bound on β–tubulin are described. In this work, the synthesis of isotopically labeled taxol analogs is described and the REDOR studies of this compound complexed to tubulin agrees with the hypothesis that palic
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Ru. "Isolation, structure elucidation and approaches to the partial synthesis of new taxol analogs." Thesis, This resource online, 1994. http://scholar.lib.vt.edu/theses/available/etd-11102009-020316/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Samaranayake, Gamini S. "Studies on the chemistry of taxol." Diss., Virginia Tech, 1992. http://hdl.handle.net/10919/39708.

Full text
Abstract:
The novel diterpenoid taxol isolated from the western yew Taxus brevifolia is one of the most important lead compounds to emerge from the search for anticancer agents from plants. It shows consistent clinical activity against ovarian cancer and may also be active against other cancers. In this study, the preparation of various taxol derivatives was investigated, with the objective of better understanding the structural requirements for activity in the taxol series. The 7-hydroxyl group of taxol was derivatized with a photoaffinity label and other reagents as a beginning of the project to under
APA, Harvard, Vancouver, ISO, and other styles
8

Johnston, Jeffrey N. "Synthetic studies directed toward polycavernoside A and Taxol(RTM) (paclitaxel) /." The Ohio State University, 1997. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487946103569429.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bourgeois, Damien. "Approche de synthèse du taxol : fermeture du cycle B par métathèse." Palaiseau, Ecole polytechnique, 2000. http://www.theses.fr/2000EPXX0032.

Full text
Abstract:
Ce travail s'inscrit dans un projet du laboratoire dont l'objectif est la synthèse du taxol, un agent antitumoral naturel. Cette molécule présente un intérêt notable en raison de son squelette particulier et de la présence de nombreuses fonctions oxygénées. Une approche convergente reposant sur la fermeture du cycle b central a 8 chainons a été étudiée. A cet effet, un précurseur du cycle c a été synthétise, et son couplage par réaction de shapiro avec un aldéhyde précurseur du cycle a été étudié. La fermeture des divers séco-taxanes ainsi obtenus par réaction de métathèse a été inefficace. En
APA, Harvard, Vancouver, ISO, and other styles
10

Mangatal, Lydie. "Dérivés antitumoraux du taxol : hémisynthèse et relations structure-activité." Paris 11, 1989. http://www.theses.fr/1989PA112093.

Full text
Abstract:
Le taxol, diterpène de type taxane, extrait difficilement des écorces de tronc de l'If (Taxus baccata L. ), est un "poison du fuseau mitotique" possédant un mode d'action unique sur la tubuline. Son hémisynthèse, ainsi que celle d'analogues structuraux a été entreprise à partir de la désacétyl-10baccatine III isolée des feuilles de l'If. L'hémisynthèse a été effectuée selon deux approches différentes. Une des voies fait intervenir une réaction d'hydroxyamination de Sharpless dont la sélectivité a été étudiée. L'activité biologique des analogues structuraux, ainsi que des intermédiaires d'hémis
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Paclitaxel (Taxol)"

1

I, Georg Gunda, American Chemical Society. Division of Chemical Health andSafety., American Chemical Society. Division of Medicinal Chemistry., and American Chemical Society. Division of Organic Chemistry., eds. Taxane anticancer agents: Basic science and current status : developed from symposia sponsored by the Divisions of Chemical Health and Safety, Medicinal Chemistry, and Organic Chemistry at the 207th National Meeting of the American Chemical Society, San Diego, California, March 13-18, 1994. The Society, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Proceedings of the second National Cancer Institute Workshop on Taxol and Taxus: Held at Alexandria, Virginia, September 23-24, 1992. U.S. Dept. of Health and Human Services, Public Health Service, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

National Cancer Institute Workshop on Taxol and Taxus (2nd 1992 Alexandria, Va.). Proceedings of the second National Cancer Institute Workshop on Taxol and Taxus: Held at Alexandria, Virginia, September 23-24, 1992. U.S. Dept. of Health and Human Services, Public Health Service, National Cancer Institute, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Office, General Accounting. Technology transfer: NIH-private sector partnership in the development of Taxol : report to the Honorable Ron Wyden, U.S. Senate. The Office, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Steinberg, Ken. Effects of structural domains of Raf-1 on the sensitivity of MCF-7 breast cancer cells to Taxol (Paclitaxel). Laurentian University, School of Graduate Studies, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Matthew, Suffness, ed. Taxol: Science and applications. CRC Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

C, Hansen Robert, and Ohio Agricultural Research and Development Center., eds. Taxus and Taxol: A compilation of research findings. Ohio State University, Ohio Agricultural Research and Development Center, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vittorio, Farina, ed. The chemistry and pharmacology of taxol and its derivatives. Elsevier, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1944-, McGuire William P., and Rowinsky Eric K. 1956-, eds. Paclitaxel in cancer treatment. M. Dekker, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Taxane Anticancer Agents: Basic Science and Current Status (Acs Symposium Series). Oxford University Press, USA, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Paclitaxel (Taxol)"

1

Casazza, Anna M., and Craig R. Fairchild. "Paclitaxel (Taxol®) Mechanisms of Resistance." In Drug Resistance. Springer US, 1996. http://dx.doi.org/10.1007/978-1-4613-1267-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Taxol (Paclitaxel)." In Encyclopedia of Genetics, Genomics, Proteomics and Informatics. Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6754-9_16716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

May, Paul, and Simon Cotton. "Taxol (Paclitaxel)." In Molecules That Amaze Us. CRC Press, 2014. http://dx.doi.org/10.1201/b17423-57.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Taxol (Paclitaxel) and Cancer Chemotherapy." In Pharmacodynamic Basis of Herbal Medicine, Second Edition. CRC Press, 2006. http://dx.doi.org/10.1201/9781420006452.ch62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Taxol (Paclitaxel) and Cancer Chemotherapy." In Pharmacodynamic Basis of Herbal Medicine. CRC Press, 2006. http://dx.doi.org/10.1201/9781420006452-68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Taxol® (Paclitaxel) and Cancer Chemotherapy." In Pharmacodynamic Basis of Herbal Medicine. CRC Press, 2001. http://dx.doi.org/10.1201/9781420041781.ch55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Taxol® (Paclitaxel) and Cancer Chemotherapy." In Pharmacodynamic Basis of Herbal Medicine. CRC Press, 2010. http://dx.doi.org/10.1201/9781420041781-59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vyas, Dolatrai M. "3 Paclitaxel (taxol®) formulation and prodrugs." In Pharmacochemistry Library. Elsevier, 1995. http://dx.doi.org/10.1016/s0165-7208(06)80017-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Taber, Douglass F. "The Sato/Chida Synthesis of Paclitaxel (Taxol®)." In Organic Synthesis. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190646165.003.0104.

Full text
Abstract:
Paclitaxel (Taxol®) 3 is widely used in the clinical treatment of a variety of cancers. Takaaki Sato and Noritaka Chida of Keio University envisioned (Org. Lett. 2015, 17, 2570, 2574) establishing the central eight-membered ring of 3 by the SmI2-mediated cyclization of 1 to 2. The starting point for the synthesis was the enantiomerically-pure enone 5, pre­pared from the carbohydrate precursor 4. Conjugate addition to 5 proceeded anti to the benzyloxy substituent to give, after trapping with formaldehyde and protection, the ketone 6. Reduction and protection followed by hydroboration led to 7, that was, after protection and deprotection, oxidized to 8. The second ring of 3 was added in the form of the alkenyl lithium derivative 9, prepared from the trisylhydrazone of the corresponding ketone. Hydroxyl-directed epoxidation of 10 proceeded with high facial selectivity, leading, after reduction and protection, to the cyclic carbonate 11. Allylic oxidation converted the alkene into the enone, while at the same time oxidizing the benzyl protecting group to the ben­zoate, to give 12. Reduction of the ketone 12 led to a mixture of diastereomers. In practice, only one of the diastereomers of 1 cyclized cleanly to 2, as illustrated, so the undesired diastereomer from the NaBH4 reduction was oxidized back to the enone for recycling. For convenience, only one of the diastereomers of 2 was carried forward. To establish the tetrasubstituted alkene of 3, the alkene of 2 was converted to the cis diol and on to the bis xanthate 13. Warming to 50°C led to the desired tet­rasubstituted alkene, sparing the oxygenation that is eventually required for 3. For convenience, to intercept 16, the intermediate in the Takahashi total synthesis, both xanthates were eliminated to give 14. Hydrogenation removed the disubsti­tuted alkene, and also deprotected the benzyl ether. Oxidation followed by Peterson alkene formation led to 15, that was carried on to the Takahashi intermediate 16 using the now-standard protocol for oxetane construction. It is a measure of the strength of the science of organic synthesis that Masahisa Nakada of Waseda University also reported (Chem. Eur. J. 2015, 21, 355) an elegant synthesis of 3 (not illustrated).
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Shu-Hui, and Vittorio Farina. "5 Paclitaxel (Taxol®) chemistry and structure— Activity relationships." In Pharmacochemistry Library. Elsevier, 1995. http://dx.doi.org/10.1016/s0165-7208(06)80019-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Paclitaxel (Taxol)"

1

Ferrero, J.-M., A.-C. Hardy-Bessard, O. Capitain, et al. "Abstract P3-13-07: A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p3-13-07.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Paclitaxel (Taxol)"

1

Sikic, Branimir I. Paclitaxel (Taxol) Resistance in Breast Cancer Cells. Defense Technical Information Center, 1996. http://dx.doi.org/10.21236/ada326396.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sikic, Branimir I. Paclitaxel (Taxol) Resistance in Breast Cancer Cells. Defense Technical Information Center, 1998. http://dx.doi.org/10.21236/ada392688.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Criswell, Tracy L., and David A. Boothman. Investigating the Role of Nuclear Clusterin (nCLU) in Lethality and Genomic Instability in Paclitaxel (Taxol) - Treated Human Breast Cancer Cells. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada418107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Criswell, Tracy L., and David A. Boothman. Investigating the Role of Nuclear Clusterin (nCLU) in Lethality and Genomic Instability in Paclitaxel (Taxol) - Treated Human Breast Cancer Cells. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada406785.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Paclitaxel (Taxol)' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography